Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines

Affiliations


Abstract

With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS, most current diagnostic and treatment algorithms need revision and updating. The diagnosis of MS relies on incorporating clinical and paraclinical findings to prove dissemination in space and in time, and exclude alternative diseases that can explain the findings at hand. The differential diagnostic workup should be guided by clinical and laboratory red flags to avoid unnecessary tests. Appropriate selection of multiple sclerosis (MS) therapies is critical to maximize patient benefit. The current guidelines review the scientific evidence supporting treatment of acute relapses, radiologically isolated syndrome, clinically isolated syndrome, relapsing remitting MS, and progressive MS. The purpose of these guidelines is to provide practical recommendations and algorithms for the diagnosis and treatment of MS based on current scientific evidence and clinical experience.

Conflict of interest statement

Declaration of Competing Interest The authors received honoraria from Biologix (the distributor for Biogen Idec across the Middle East and North Africa region) for serving on their advisory board and from other pharmaceutical companies including Novartis, GSK, Bayer, Merck, Sanofi and Roche. The manuscript represents the views and opinions of the members involved in the development of the guidelines. There is no industrial or pharmaceutical support or bias in the selection of the members or the recommendations reached. This effort was sponsored and carried out under the supervision of MENACTRIMS (The Middle East and North Africa Committee for Treatment and Research In Multiple Sclerosis).


Similar articles

Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS).

Yamout B, Alroughani R, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J, Hashem S, Alsharoqi I, Sahraian M, Khoury S, Alkawi Z, Koussa S, Zakaria M, Al Khaburi J, Alsaadi T, Bohlega S.Curr Med Res Opin. 2015;31(7):1349-61. doi: 10.1185/03007995.2015.1047750. Epub 2015 May 29.PMID: 25946578

Differential diagnosis of suspected multiple sclerosis: a consensus approach.

Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH.Mult Scler. 2008 Nov;14(9):1157-74. doi: 10.1177/1352458508096878. Epub 2008 Sep 19.PMID: 18805839 Free PMC article.

Consensus guidelines for the diagnosis and treatment of multiple sclerosis.

Yamout B, Alroughani R, Al-Jumah M, Khoury S, Abouzeid N, Dahdaleh M, Alsharoqi I, Inshasi J, Hashem S, Zakaria M, ElKallab K, Alsaadi T, Tawfeek T, Bohlega S.Curr Med Res Opin. 2013 Jun;29(6):611-21. doi: 10.1185/03007995.2013.787979. Epub 2013 Apr 22.PMID: 23514115

Classification, diagnosis, and differential diagnosis of multiple sclerosis.

Katz Sand I.Curr Opin Neurol. 2015 Jun;28(3):193-205. doi: 10.1097/WCO.0000000000000206.PMID: 25887774 Review.

Recommendations for diagnosis and management of multiple sclerosis.

Kes VB, Zavoreo I, Serić V, Solter VV, Cesarik M, Hajnsek S, Pasić MB, Gabelić T, Silvio B, Butković SS, Lusić I, Grbelja LD, Vladić A, Bielen I, Antoncić I, Demarin V; Croatian Society for Neurovascular Disorders of Croatian Medical Association; Croatian Society of Neurology of Croatian Medical Association; Referral Center for Demyelinating Diseases of the CNS.Acta Clin Croat. 2012 Mar;51(1):117-35.PMID: 22920014


Cited by

Multiple Sclerosis-A Demyelinating Disorder and Its Dental Considerations-A Literature Review with Own Case Report.

Al Johani K, Fudah M, Al-Zahrani M, Abed H, Srivastava KC, Shrivastava D, Cicciù M, Minervini G.Brain Sci. 2023 Jun 29;13(7):1009. doi: 10.3390/brainsci13071009.PMID: 37508941 Free PMC article. Review.

Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.

Henderson M, Horton DB, Bhise V, Pal G, Bushnell G, Dave CV.JAMA Neurol. 2023 Jul 10:e232125. doi: 10.1001/jamaneurol.2023.2125. Online ahead of print.PMID: 37428482

Cerebral Venous Sinus Thrombosis induced By Hypercoagulation in Patient With Systemic Lupus Erythematosus: A Case Report and Literature Review.

Amalia L.J Blood Med. 2023 Jan 10;14:1-6. doi: 10.2147/JBM.S387075. eCollection 2023.PMID: 36647371 Free PMC article.

Safety and efficacy of tyrosine kinase inhibitors for the treatment of multiple sclerosis: A systematic review and meta-analysis from randomized controlled trials.

Yan Z, Gu F, Wang Z, Meng J, Tao X, Dai Q, Wang W, Liu M, Wang Z.Front Neurol. 2022 Sep 26;13:933123. doi: 10.3389/fneur.2022.933123. eCollection 2022.PMID: 36226084 Free PMC article.

The Socioeconomic and Psychological Impact of the COVID-19 Pandemic on People with Multiple Sclerosis in Turkey.

Gündüz T, Uzunköprü C, Demir S, Tütüncü M, Seferoğlu M, Gümüş H, Şen S, Doğan İG, Tütüncü M, Çalikoğlu YS, Beckmann Y, Kocaman AS, Siva A.Noro Psikiyatr Ars. 2022 Aug 15;59(3):226-231. doi: 10.29399/npa.28189. eCollection 2022.PMID: 36160079 Free PMC article.


KMEL References